Ignored, Off-Patent and Backed by Research: The Parasite Cancer Connection
- shelleybholisticnu
- 1 day ago
- 1 min read
Some of the most overlooked pieces in chronic illness and cancer aren’t new... they’re just not profitable.
Ivermectin, mebendazole and fenbendazole are off-patent drugs - their patents expired decades ago, which means there’s little financial incentive to study or promote them today.
Fun fact: Ivermectin (yes, the one nicknamed 'horse dewormer') won the Nobel Prize in 2015 for its life-saving impact in humans.
Shoutout to brave doctors like Dr. William Makis, who's faced backlash for exploring these off-patent options that challenge the multi-billion-dollar cancer industry.
From his insights:
👉 Nearly 400 papers on ivermectin + cancer
👉 Johns Hopkins holds patents on mebendazole for cancers (e.g., brain tumors)
👉 He's consulted thousands of patients trying ivermectin/fenbendazole combos, with many (including stage 4) reporting tumors shrinking and progress that surprised their oncologists.
He now consults with thousands of cancer patients worldwide and is beginning to publish clinical observations on dosing and combinations.
When treatments are inexpensive, off-patent and not highly profitable, they're not likely to receive the attention they deserve.
@followers Before jumping into a parasite cleanse, there’s a right order... and most people skip it. I explain it here.
Comments